Trial reportDrug design, development and therapy2025
Effects of Subanesthetic Esketamine on Postoperative Sleep Quality Through EEG Analysis in Breast Cancer Patients: A Randomized Clinical Trial.
Trial report in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Perioperative esketamine for prevention of postoperative sleep disturbance after anesthesia: a systematic review and meta-analysis of randomized controlled trials.Frontiers in pharmacology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Postoperative sleep disturbance (POSD) is prevalent following breast cancer surgery, impairing postoperative recovery. However, effective interventions and underlying mechanisms remain unclear. This study aims to evaluate whether intravenous subanesthetic esketamine improves postoperative sleep quality and its association with electroencephalogram (EEG) frequency band changes in breast cancer patients. Methods: In this randomized, double-blind, placebo-controlled trial, patients undergoing breast cancer surgery received either intravenous esketamine (0.2 mg/kg induction, 0.4 mg/kg/h maintenance) or placebo during anesthesia. Both groups received intraoperative EEG monitoring. The primary outcome was POSD incidence at 24 hours assessed by the Pittsburgh Sleep Quality Index (PSQI). Secondary outcomes included PSQI scores at 72 hours, Self-Rating Anxiety Scale (SAS) and Self-Rating Depression Scale (SDS) scores, Visual Analog Scale (VAS) pain scores, and intraoperative EEG parameters. Results: POSD incidence was significantly reduced in the esketamine group compared with the control group (27.3% [16/58] vs 51.7% [30/58]; odds ratio, 0.36; 95% CI, 0.16-0.77; P = 0.014). Moreover, the esketamine group demonstrated significantly lower PSQI scores at both 24 hours (median [IQR], 2 [1-5] vs 4 [4-8]; P < 0.001) and 72 hours (1 [0-2.5] vs 3.5 [2.75-5]; P < 0.001). The esketamine group exhibited significantly higher intraoperative gamma-band relative power spectral density (mean [SD], 0.74 [0.25] vs 0.52 [0.18]; P < 0.001), which was independently associated with reduced POSD risk in multivariate analysis (odds ratio, 0.63; 95% CI, 0.40-0.97; P = 0.039). Conclusion: Subanesthetic esketamine significantly reduced the incidence of POSD and lowered PSQI scores. Importantly, esketamine was associated with enhanced intraoperative gamma-band EEG activity, which was independently associated with reduced POSD risk, suggesting that modulation of specific cortical oscillations may underlie its sleep-enhancing effects. Trial Registration: Chinese Clinical Trial Registry Identifier: ChiCTR2400092257.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.